Real world incidence, severity and timing of adverse events (AEs) among patients with metastatic non-small cell lung cancer (NSCLC) receiving second-line (2L) immuno-oncology (IO) therapy vs chemotherapy (C)
Gutierrez, M.E., Norden, A.D., Lane, D.C., Canavan, B.F., Nwokeji, E.D., Xu, Y., Kaur, S., Goldberg, S.L., Noh, L., Siegartel, L., Whittington, J., Tuell, K., Korytowsky, B.
Published in Annals of oncology (01.10.2018)
Published in Annals of oncology (01.10.2018)
Get full text
Journal Article